Megan Miller

Megan Miller

Auto-generated profile, based on publicly available information

Megan Miller

Janssen Research & Development, LLC, Spring House, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
KRKristian Reich
Kristian Reich
KGK. B. Gordon
K. B. Gordon
BSB. E. Strober
B. E. Strober
AAAnd April W. Armstrong
And April W. Armstrong
MMM. Miller
M. Miller
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
Background Psoriasis is a chronic disease requiring long-term therapy. Objectives Physician- and patient-reported outcomes (PROs) were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. Methods A total of 1829 patients were randomized at baseline to receive guselkumab 100 mg every-8-weeks, placebo, or adalimumab; placebo patients crossed-over to guselkumab at week 16. Adalimumab patients crossed-over to guselkumab at week 52 in VOYAGE 1, and randomized-withdrawal/retreatment occurred at weeks 28-76 in VOYAGE 2; all patients then received open-label guselkumab through week 252. Efficacy and HRQoL endpoints were analyzed through week 252. Safety was monitored through week 264. Results The proportions of patients in the guselkumab group who achieved clinical responses at week 252 in VOYAGE 1 and VOYAGE 2, respectively, were: 84.1% and 82.0% (PASI90); 82.4% and 85.0% (IGA0/1); 52.7% and 53.0% (PASI100); and 54.7% and 55.5% (IGA0). HRQoL endpoints were achieved as follows: 72.7% and 71.1% of patients (Dermatology Life Quality Index 0/1 or no effect on patient’s life); 42.4% and 42.0% (Psoriasis Symptoms and Signs Diary [PSSD] symptom score=0); and 33.0% and 31.0% (PSSD sign score=0). In VOYAGE 2 only, approximately 45% of patients achieved ≥5-point reduction in SF-36 Physical/Mental component scores and 80% reported no anxiety/depression (Hospital Anxiety and Depression scores <8). Similar findings were reported for adalimumab crossovers. These effects were maintained from week 52 in VOYAGE 1 and week 100 in VOYAGE 2. No new safety signals were identified. Conclusions Guselkumab maintains high levels of clinical response and PRO improvement through 5 years in patients with moderate-to-severe psoriasis.

31 October 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
BSBruce Strober
Bruce Strober
LCLaura C. Coates
Laura C. Coates
MLMark G. Lebwohl
Mark G. Lebwohl
ADAtul Deodhar
Atul Deodhar
ELEvan Leibowitz
Evan Leibowitz
PRProton Rahman
Proton Rahman
Introduction The benefit/risk profiles of biologics can be affected by comorbidities, certain demographic characteristics, and concomitant medications; therefore, it is important to evaluate the long-term safety profiles of biologics across broad patient populations. Guselkumab was well tolerated and efficacious across individual pivotal clinical studies in adults with moderate-to-severe psoriasis and/or active psoriatic arthritis (PsA). Objectives The objective of the current analysis was to evaluate guselkumab safety in a large population of patients with psoriatic disease by pooling adverse event (AE) data from 11 phase II/III studies (seven in psoriasis; four in PsA). Methods Guselkumab was generally administered as 100 mg subcutaneous injections at Week 0, Week 4, then every 8 weeks (Q8W) in psoriasis studies and at Week 0, Week 4, then every 4 weeks (Q4W) or Q8W in PsA studies. Safety data were summarized for the placebo-controlled period (Weeks 0–16 in psoriasis; Weeks 0–24 in PsA) and through the end of the reporting period (up to 5 years in psoriasis; up to 2 years in PsA). Using the integrated data, incidence rates of key AEs were determined post hoc, adjusted for duration of follow-up, and reported per 100 patient-years (PYs). AE rates were also determined in subgroups of patients defined by sex, age, body mass index (BMI), and prior biologic use. Results During the placebo-controlled period, 1061 patients received placebo (395 PYs) and 2257 received guselkumab (856 PYs). Through the end of the reporting period, 4399 guselkumab-treated patients contributed 10,787 PYs of follow-up. During the placebo-controlled period, in the guselkumab and placebo groups, respectively, rates of AEs were 281 versus 272/100 PYs, and infections were 76.0 versus 72.2/100 PYs. Rates of serious AEs (5.6 vs. 7.8/100 PYs), AEs leading to discontinuation (4.9 vs. 6.6/100 PYs), serious infections (1.0 vs. 2.3/100 PYs), malignancy (0.59 vs. 0.25 patients/100 PYs), and major adverse cardiovascular events (MACE; 0.35 vs. 0.25/100 PYs) were low and comparable between guselkumab and placebo. Among guselkumab-treated patients, safety event rates through the end of the reporting period were numerically lower than or comparable with rates observed during the placebo-controlled period: AEs, 164/100 PYs; infections, 61.2/100 PYs; serious AEs, 5.4/100 PYs; AEs leading to discontinuation, 1.8/100 PYs; serious infections, 1.0/100 PYs; malignancy, 0.6/100 PYs; and MACE, 0.3/100 PYs. No AEs of Crohn’s disease, ulcerative colitis, or active tuberculosis were reported among guselkumab-treated patients. In the psoriasis studies, no opportunistic infections were reported among guselkumab-treated patients. Three AEs of opportunistic infections were reported in guselkumab-treated patients with PsA (0.14/100 PYs; all after Week 52 in DISCOVER-2). AE rates were largely consistent across subgroups of guselkumab-treated patients defined by sex, age, BMI, and prior biologic use. Conclusions In this analysis of 4399 guselkumab-treated patients with psoriatic disease followed for 10,787 PYs, guselkumab had a favorable AE profile. AE rates were similar between guselkumab- and placebo-treated patients and were consistent throughout long-term guselkumab treatment and across broad subgroups of patients with psoriatic disease. Clinical Trials Registrations Clinicaltrials.gov identifiers: NCT01483599, NCT02207231, NCT02207244, NCT02203032, NCT02905331, NCT03090100, NCT02325219, NCT02319759, NCT03162796, NCT03158285, and NCT03796858. Graphical Abstract

1 October 2021 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
LFLaura E. Fischer
Laura E. Fischer
BWBruce M. Wolfe
Bruce M. Wolfe
NFNora Fino
Nora Fino
MEMiriam R. Elman
Miriam R. Elman
DFDavid R. Flum
David R. Flum
DKDavid E. Kleiner
David E. Kleiner
Postbariatric hypoglycemia (PBH) can be a devastating complication for which current therapies are often incompletely effective. More information is needed regarding frequency, incidence, and risk factors for PBH. To examine hypoglycemia symptoms following Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) and baseline and in-study risk factors. Multicenter, at 10 US hospitals in 6 geographically diverse clinical centers. A prospective, longitudinal cohort study of adults undergoing RYGB or LAGB as part of clinical care between 2006 and 2009 were recruited and followed until January 31, 2015, with baseline and annual postoperative research assessments. We analyzed baseline prevalence and post-operative incidence and frequency of self-reported hypoglycemia symptoms as well as potential preoperative risk factors. In all groups, postoperative prevalence of hypoglycemia symptoms was 38.5%. Symptom prevalence increased postoperatively from 2.8%-36.4% after RYGB in patients without preoperative diabetes (T2D), with similar patterns in prediabetes (4.9%-29.1%). Individuals with T2D had higher baseline hypoglycemia symptoms (28.9%), increasing after RYGB (57.9%). Hypoglycemia symptoms were lower after LAGB, with 39.1% reported hypoglycemia symptoms at only 1 postoperative visit with few (4.0%) having persistent symptoms at 6 or more annual visits. Timing of symptoms was not restricted to the postprandial state. Symptoms of severe hypoglycemia were reported in 2.6-3.6% after RYGB. The dominant risk factor for postoperative symptoms was preoperative symptoms; additionally, baseline selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitor use was also associated with increased risk in multivariable analysis. Weight loss and regain were not related to hypoglycemia symptom reporting. Hypoglycemia symptoms increase over time after RYGB, particularly in patients without diabetes. In a small percentage, symptoms can be persistent or severe and require hospitalization. Preoperative hypoglycemia symptoms and SSRI/SNRI use in RYGB patients without diabetes is associated with increased risk of symptoms.

10 September 2020 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
KRKristian Reich
Kristian Reich
AAAnd April W. Armstrong
And April W. Armstrong
PFPeter Foley
Peter Foley
MSMichael Song
Michael Song
MMMegan Miller
Megan Miller
KGKenneth B. Gordon
Kenneth B. Gordon

1 January 2021 in Geriatric Orthopaedic Surgery & Rehabilitation
Verified
Journal Article
Open access
PDF file
PHPhuong Anh N Huynh
Phuong Anh N Huynh
MMMegan Miller
Megan Miller
RWRyan Will
Ryan Will
Tranexamic acid can decrease blood loss related to surgery and trauma. The primary objective of this study is to examine if the use of a single dose of peri-operative TXA significantly decreases the rate of allogenic blood transfusions in the setting of operative care of hip fractures. Secondary objectives included examining if total blood loss was decreased by TXA in operative hip fractures as well as examining the safety of TXA by measuring the rates venous thromboembolism (VTE). Retrospective chart review of 505 patients who were operatively treated for hip fractures at a single facility was performed. In a non-randomized fashion, 307 patients received TXA and 198 patients did not. Patients received 1 gram of TXA prior to incision. Blood transfusion was the primary end point. Blood loss was calculated using the hemoglobin balance method. Chart was reviewed for VTE events during hospitalization. 505 patients were analyzed. The use of single perioperative dose of TXA in the surgical management of hip fracture resulted in absolute risk reduction of transfusion of 7.7% and relative risk reduction of transfusion by 29%. This was statistically significant with P =.04. Patients who received TXA on average lost 235 ml less blood compared to those who did not receive TXA (P <.0001). No increase in VTE events were found in either group during hospitalization. This study supports the use of TXA is decrease blood loss and transfusion rates in patients with hip fractures. TXA can be used routinely to decrease complications in this usually fragile population.

25 June 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
ABAndrew Blauvelt
Andrew Blauvelt
KGKenneth B. Gordon
Kenneth B. Gordon
RLRichard G. Langley
Richard G. Langley
PBPatrick J. Branigan
Patrick J. Branigan
YCYanqing Chen
Yanqing Chen
AAAnd April W. Armstrong
And April W. Armstrong